Nanoparticles for Delivery of Agents to Fetal Lungs


Authors: S.J. Ullrich, M. Freedman-Weiss, S. Ahle, D.H. Stitelman, et. al.

Journal: Acta Biomaterilia

DOI: 10.1016/j.actbio.2021.01.024

Publication - Abstract

March 15, 2021

Abstract

Fetal treatment of congenital lung disease, such as cystic fibrosissurfactant protein syndromes, and congenital diaphragmatic hernia, has been made possible by improvements in prenatal diagnostic and interventional technology. Delivery of therapeutic agents to fetal lungs in nanoparticles improves cellular uptake. The efficacy and safety of nanoparticle-based fetal lung therapy depends on targeting of necessary cell populations. This study aimed to determine the relative distribution of nanoparticles of a variety of compositions and sizes in the lungs of fetal mice delivered through intravenous and intra-amniotic routes. Intravenous delivery of particles was more effective than intra-amniotic delivery for epithelial, endothelial and hematopoietic cells in the fetal lung. The most effective targeting of lung tissue was with 250nm Poly-Amine-co-Ester (PACE) particles accumulating in 50% and 44% of epithelial and endothelial cells. This study demonstrated that route of delivery and particle composition impacts relative cellular uptake in fetal lung, which will inform future studies in particle-based fetal therapy.

Advanced Search

close
  • Publications
  • Application Notes
  • Posters
  • Workshops
  • Videos & Webinars
  • Articles
Search

Browse by Category

  • Application
    • Diagnostic and Imaging
    • Genetic Medicine
    • Hematology
    • Metabolic Disorders
    • Neuroscience
    • Oncology
    • Skeletal Disorders
    • Targeted Drug Delivery
    • Vaccines
    • Other Applications
    • Cell therapy
  • Formulation
    • Liposomes
    • Nucleic Acid Lipid Nanoparticles
    • Polymeric Nanoparticles
    • Other Formulations
  • Payload
    • DNA
    • microRNA
    • mRNA
    • siRNA
    • Small Molecule Drugs
    • Other Payloads


related content

Publication - Summary

Researchers from Holger J. Møller's group at Aarhus University in Denmark have published an approach to a cancer immunotherapy that involves altering the function of tumour associated macrophages (TAMs) to fight cancer.  TAMs can take on two main phenotypes: the tumou...
Read More


Publication - Abstract

In a publication written in August 2021, scientists Rabanel et al. from the INRS Centre Armand-Frappier Santé Biotechnologie and the Université de Montréal sought to tackle a fundamental challenge in developing pharmaceutical interventions for a variety of br...
Read More


Sign Up and Stay Informed
Sign up today to automatically receive new Cytiva, formerly Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.